Antisense therapy in clinical oncology: Preclinical and clinical experiences

Molecular Biotechnology

Volumn 33, Issue 3, 2006, Pages 221-238

  Tamm, Ingo ^a   Wagner, Mandy ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NONE

Author keywords

Antisense oligonucleotides; bcl 2; Cancer; DNA methyltransferase; H RAS; Leukemia; Protein kinase A; Protein kinase C ; RAF kinase; Targeted therapy

Indexed keywords

DISEASES; DNA; DRUG THERAPY; ENZYMES; PATHOLOGY; TUMORS;

ANTISENSE OLIGONUCLEOTIDES; DNA METHYLTRANSFERASE; LEUKEMIA; TARGETED THERAPY;

BIOMEDICAL ENGINEERING;

AEG 35156; ANTISENSE OLIGONUCLEOTIDE; AP 12009; CGP 69846A; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOCETAXEL; FLUDARABINE; FOMIVIRSEN; G 4460; GENE EXPRESSION MODULATOR 231; GTI 2040; GTI 2501; ISIS 23722; ISIS 2503; ISIS 3521; LERAFAON; LR 3001; LY 2181308; MG 98; MITOXANTRONE; OBLIMERSEN; OGX 011; PROTEIN BCL 2; PROTEIN KINASE C ALPHA; RAF PROTEIN; RITUXIMAB; SURVIVIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTHRALGIA; ASTHENIA; BREAST CANCER; CANCER; CANCER RESEARCH; CANCER THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; COLON CANCER; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG TARGETING; EXPERIMENTAL MODEL; FATIGUE; FEVER; GENE EXPRESSION REGULATION; HEAD AND NECK CANCER; HUMAN; HYBRIDIZATION; HYPOTENSION; KIDNEY CANCER; LEUKEMIA; LIVER CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MULTIPLE MYELOMA; MYALGIA; NEUTROPENIA; NONHODGKIN LYMPHOMA; ONCOGENE H RAS; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; RETINITIS; REVIEW; THROMBOCYTOPENIA;

CLINICAL TRIALS AS TOPIC; CYTOMEGALOVIRUS RETINITIS; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE;

CYTOMEGALOVIRUS;

EID: 33748342736     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1385/MB:33:3:221     Document Type: Review

References (95)

1. Buolamwini, J. K. (1999) Novel anticancer drug discovery. Curr. Opin. Chem. Biol. 3, 500-509.
2. Clark, R. E. (2000) Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems. Leukemia 14, 347-355.
3. Baker, B. F. and Monia, B. P. (1999) Novel mechanisms for antisense-mediated regulation of gene expression. Biochim. Biophys. Acta 1489, 3-18.
4. Crooke, S. T. (1999) Molecular mechanisms of action of antisense drugs. Biochim. Biophys. Acta 1489, 31-44.
5. Gewirtz, A. M. (2000) Oligonucleotide therapeutics: a step forward. J. Clin. Oncol. 18, 1809-1811.
6. Koller, E., Gaarde, W. A., and Monia, B. P. (2000) Elucidating cell signaling mechanisms using antisense technology. Trends Pharmacol. Sci. 21, 142-148.
7. Khuri, F. R. and Kurie, J. M. (2000) Antisense approaches enter the clinic. Clin. Canc. Res. 6, 1607-1610.
8. Tamm, I., Dörken, B., and Hartmann, G. (2001) Antisense therapy in oncology: new hope for an old idea? Lancet 358, 489-497.
9. Waters, J. S., Webb, A., Cunningham, D., et al. (2000) Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-hodgkin's lymphoma. J. Clin. Oncol. 18, 1812-1823.
10. Brysch, W., Rifai, A., Tischmeyer, W., and Schlingensiepen, K.-H. (1996) Antisense-mediated inhibition of protein synthesis. In: Antisense Therapeutics (Agrawal, S., ed.), Humana Press, Totowa, NJ, pp. 159-182.
11. Cotter, F. E. (1999) Antisense therapy of hematologic malignancies. Sem. Hematol. 36, 9-14.
12. Levin, A. A. (1999) A review of issues in the pharmacokinetics and toxicology of phophorothioate antisense oligonucleotides. Biochim. Biophys. Acta 1489, 69-84.
13. de Smet, M. D., Meenken, C. J., and van den Horn, G. J. (1999) Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul. Immunol. Inflamm. 7, 189-198.
14. Adams, J. M. and Cory, S. (1998) The bcl-2 protein family: arbiters of cell survival. Science 281, 1322-1326.
15. Reed, J. C. (1995) Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr. Opin. Oncol. 7, 541-546.
16. Genta, Inc. www.genta.com. Date accessed: 2/10/06
17. Leonard, J. P., Coleman, M., Vose, J., Hainworth, J. D., and Itri, L. M. (2003) Phase II study of oblimersen sodium (G3139) alone and with R-CHOP in mantle cell lymphoma (MCL). Proc. Am. Soc. Clin. Oncol. 22, 566.
18. O'Brien, S. M., Rai, K. R., and Peterson, B. L. (2003) The addition of rituximab to fludarabine significantly improves progression-free and overall survival in previously untreated chronic lymphocytic leukemia (CLL) patients. Blood 103, 432.
19. Chanan-Khan, A. (2005) Bcl-2 antisense therapy in B-cell malignancies. Blood Rev. 19, 213-221.
20. Rai, K., Moore, J. O., and Boyd, T. E. (2001) Phase 3 randomized trial of fludarabine/cyclophosphamide chemotherapy with or without oblimersen sodium (Bcl-2 antisense; Genasense; G3139) for patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood 104, 338.
21. Gokhale, P. C., Zhang, C., and Newsome, J. T. (2002) Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome. Clin. Cancer Res. 8, 3611-3621.
22. Morris, M. J., Tong, W. P., Cordon-Cardo, C., et al. (2002) Phase I trial of bcl-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin. Canc. Res. 8, 679-683.
23. Cerroni, L., Soyer, H. P., and Kerl, H. (1995) Bcl-2 expression in cutaneous malignant melanoma and benign melanocytic nevi. Am. J. Dermatophatol. 17, 7-11.
24. Jansen, B., Wacheck, V., Heere-Reess, E., et al. (2000) Chemosensitization of malignant melanoma by BCL2 antisense therapy. Lancet 356, 1728-1733.
25. Gleave, M. E. and Monia, B. P. (2005). Antisense therapy for cancer. Nature Rev. Cancer 5, 468-479.
26. Chen, H. X., Marshall, J. L., Trocky, N., et al. (2000) A phase I study of bcl-2 antisense G3139 (GENTA) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Proc. Am. Soc. Clin. Oncol. 19, 178a.
27. de Bono, J. S., Rowinsky, E. K., Kuhn, J., et al. (2001) Phase I pharmacokinetic (pk) and pharmacodynamic (pd) trial of bcl-2 (Genasense) and docetaxel (D) in hormone refractory prostate cancer. Proc. Am. Soc. Clin. Oncol. 20, 474a.
28. Tolcher, A. W., Kuhn, J., Basler, J., et al. (2000) A phase I, pharmacokinetic and biologic correlative study of G3139 (Bcl-2 antisense oligonucleotide) and Docetaxel in patients with hormone-refractory prostate cancer (HRPC). Proc. Am. Soc. Clin. Oncol. 19, 527a.
29. Rudin, C., Otterson, G. A., George, C. M., Mauer, A. M., Szeto, L., and Vokes, E. E. (2001) A phase I/II trial of genasense and paclitaxel in chemorefractory small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 20, 1283a.
30. Chi, K. N., Gleave, M. E., Klasa, R., et al. (2001) A phase I dose-finding study of combined treatment with an antisense bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastastic hormone-refractory prostate cancer. Clin. Canc. Res. 7, 3920-3927.
31. Ochoa, L., Kuhn, J., Salinas, R., et al. (2001) A phase I, pharmacokinetic, and biologic correlative study of G3139 and irinotecan (CPT-11) in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 21, 297a.
32. Marcucci, G., Bloomfield, C. D., Balcerzak, S. P., et al. (2001) Biologic activity of G3139 (Genasense), a bcl-2 antisense (AS), in refractory (REF) or relapsed (REL) acute leukemia (AL). Proc. Am. Soc. Clin. Oncol. 20, 1149a.
33. Bollag, K. and McCormick, F. (1991). Regulators and effectors of ras protein. Annu. Rev. Cell Biol. 7, 601-632.
34. Bos, J. L. (1989). Ras oncogenes in human cancer: a review. Cancer Res. 49, 4682-4689.
35. Eckhardt, S. G., Rizzo, J., Sweeney, K. R., et al. (1999) Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. J. Clin. Oncol. 17, 1095-1104.
36. O'Dwyer, P. J., Stevenson, J. P., Gallagher, M., et al. (1999) c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). Clin. Canc. Res. 5, 3977-3982.
37. Stevenson, J. P., Yao, K. S., Gallagher, M., et al. (1999). Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J. Clin. Oncol. 17, 2227-2236.
38. Cunningham, C. C., Holmlund, J. T., Schiller, J. H., et al. (2000) A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin. Cancer Res. 6, 1626-1631.
39. Rudin, C. M., Holmlund, J., Fleming, G. F., et al. (2001) Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin. Cancer Res. 7, 1214-1220.
40. Oza, A. M., Eisenhauer, E., Swenerton, K., et al. (2000) Phase II study of c-raf kinase antisense oligonucleotide ISIS 5132 in patients with recurrent ovarian cancer. Proc. Am. Soc. Clin. Oncol. 19, 530a.
41. Coudert, B., Anthoney, A., Fiedler, W., et al. (2001) Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC). Eur. J. Cancer 37, 2194-2198.
42. Kasid, U. and Dritschilo, A. (2003) RAF antisense oligonucleotide as a tumor radiosensitizer. Oncogene 22, 5876-5884.
43. Rudin, C. M., Marshall, J. L., and Huang, C. H. (2004) Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin. Cancer Res. 10, 7244-7251.
44. http://clinicaltrials.gov. Date accessed: 2/10/06
45. Cunningham, C. C., Holmlund, J. T., Geary, R. S., et al. (2001) A phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer 92, 1265-1271.
46. Saleh, M., Posey, J., Pleasani, L., et al. (2000) A phase II trial of ISIS 2503, an antisense inhibitor of H-ras, as first line therapy for advanced colorectal carcinoma. Proc. Am. Soc. Clin. Oncol. 19, 320a.
47. Perez, R. P., Smith, J. W. III, Alberts, S. R., et al. (2001) Phase II trial of ISIS 2503, an antisense inhibitor of H-ras, in patients (pts) with advanced pancreatic carcinoma (ca). Proc. Am. Soc. Clin. Oncol. 20, 628a.
48. Dang, T., Johnson, D. H., Kelly, K., Rizvi, N., Holmlund, J., and Dorr, A. (2001) Multicenter phase II trial of an antisense inhibitor of H-ras (ISIS-2503) in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20, 1325a.
49. Luger, S. M., O'Brien, S. G., Ratajczak, J., et al. (2002) Oligonucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study. Blood 99, 1150-1158.
50. Vidal, L., Leslie, M., and Sludden, J. (2005) A phase I and pharmacodynamic study of a 7 day infusion schedule of the DNMT1 antisense compound MG98. Proc. Am. Soc. Clin. Oncol. 23, 3070.
51. http://www.methylgene.com. Date accessed: 2/10/06
52. Siu, L. L., Gelmon, K. A., Moore, M. J., et al. (2000) A phase I and pharmacokinetik (PK) study of the human DNA methyltransferase (Metase) antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Proc. Am. Soc. Clin. Oncol. 19, 250a.
53. Wang, H., Cai, Q., Zeng, X., Yu, D., Agrawal, S., and Zhang, R. (1999) Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration. Proc. Natl. Acad. Sci. USA 96, 13,989-13,994.
54. Goel, S., Cho-Chung, Y. S., Nesterova, M. V., et al. (2002) Phase I study monitoring extracellular PKA (ECPKA) levels in a continous intravenous infusion (CIV) with GEM231, a second generation antisense oligonucleotide targeted against PKA RIalpha. Proc. Am. Soc. Clin. Oncol. 21, 1b.
55. Hau, P., Bogdahn, U., Schulmeyer, F., et al. (2002) TGF-beta2 antisense oligonucleotide AP 12009 administered intratumorally to patients with malignant glioma in a clinical phase I/II dose escalation study: safety and preliminary efficacy data. Proc. Am. Soc. Clin. Oncol. 21, 28a.
56. Hau, P., Kunst, M., and Pichler, J. (2005) Targeted downregulation of TGF-beta2 as immunotherapy for high-grade glioma: a phase IIb study. Proc. Am. Soc. Clin. Oncol. 23, 1537.
57. Schlingensiepen, K, Bischof, A., and Egger, T. (2005) Targeted downregulation of TGF-beta2 in pancreatic carcinoma: a phase I/II dose escalation study to evaluate the safety and tolerability of the antisense oligonucleotide AP 12009. Proc. Am. Soc. Clin. Oncol. 23, 4253.
58. Deveraux, Q. and Reed, J. C. (1998) IAP family proteins - suppressors of apoptosis. Genes & Dev. 13, 239-252.
59. Tamm, I., Kornblau, S. M., Segall, H., et al. (2000) Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin. Cancer Res. 6, 1796-1803.
60. Deveraux, Q., Takahashi, R., Salvesen, G. S., and Reed, J. C. (1997) X-linked IAP is a direct inhibitor of cell death proteases. Nature 388, 300-303.
61. Takahashi, R., Deveraux, Q., Tamm, I., et al. (1998) A single BIR domain of XIAP sufficient for inhibiting caspases. J. Biol. Chem. 273, 7787-7790.
62. Holcik, M., Yeh, C., Korneluk, R. G., and Chow, T. (2000) Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. Oncogene 19, 4174-4177.
63. Bilim, V., Kasahara, T., Hara, N., Takahashi, K., and Tomita, Y. (2003) Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistance TCC in vitro. Intl. J. Cancer 103, 29-37.
64. Sasaki, H., Sheng, Y., Kotsuji, F., and Tsang, B. (2000) Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res. 60, 5659-5666.
65. Hu, Y., Cherton-Horvat, G., and Dragowska, V. (2003) Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin. Cancer Res. 9, 2826-2836.
66. Schimmer, A. (2004) Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res. 64, 7183-7190.
67. Dierlamm, J., Baens, M., Wlodarska, I., et al. (1999) The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 93, 3601-3609.
68. Baens, M., Maes, B., Steyls, A., Geboes, K., De Wolf-Peeters, C., and Marynen, P. (1999) Fusion between the apoptosis inhibitor gene API2 and a novel 18q gene MLT, rearranged in the t(11;18)(q21;q21), marks half of the gastro-intestinal MALT-type lymphomas without large cell proliferation. Blood 94, 384a.
69. Ambrosini, G., Adida, C., and Altieri, D. C. (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Med. 3, 917-921.
70. Tamm, I., Wang, Y., Sausville, E., et al. (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58, 5315-5320.
71. Lu, C. D., Altieri, D. C., and Tanigawa, N. (1998) Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 58, 1808-1812.
72. Islam, A., Kageyama, H., Takada, N., et al. (2000) High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19, 617-623.
73. Kasof, G. M. and Gomes, B. C. (2000) Livin, a novel inhibitor-of- apoptosis (IAP) family member. J. Biol. Chem. 158, 431-438.
74. Kawasaki, H., Altieri, D. C., Lu, C. D., Toyoda, M., Tenjo, T., and Tanigawa, N. (1998) Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 58, 5071-5074.
75. Monzo, M., Rosell, R., Felip, E., et al. (1999) A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J. Clin. Oncol. 17, 2100-2104.
76. Sarela, A. I., Macadam, R. C., Farmery, S. M., Markham, A. F., and Guillou, P. J. (2000) Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46, 645-650.
77. Swana, H. S., Grossman, D., Anthony, J. N., Weiss, R. M., and Altieri, D. C. (1999). Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N. Engl. J. Med. 341, 452-453.
78. Tanaka, K., Iwamoto, S., Gon, G., Nohara, T., Iwamoto, M., and Tanigawa, N. (2000) Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin. Cancer Res. 6, 127-134.
79. Adida, C., Berrebi, D., Peuchmaur, M., Reyes-Mugica, M., and Altieri, D. C. (1998) Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 351, 882-883.
80. Li, F., Ackermann, E. J., Bennett, C. F., et al. (1999) Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nature Cell Biol. 1, 461-466.
81. Suzuki, A., Hayashida, M., Ito, T., et al. (2000) Survivin initiates cell cycle entry by the competitive interaction with Cdk-4/p16INK4a and Cdk2/Cyclin E complex activation. Oncogene 19, 3225-3234.
82. Li, F., Ambrosini, G., Chu, E. Y., et al. (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396, 580-584.
83. Reed, J. C. (1999) Survivin' cell-separation anxiety. Nature Cell Biol. 1, 199-200.
84. Olie, R. A., Simoes-Wust, A. P., and Baumann, B. (2000) A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 60, 2805-2809.
85. Xia, C., Xu, Z., and Yuan, X. (2002) Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol. Cancer Ther. 1, 687-694.
86. Tu, S. P., Jiang, X. H., and Lin, M. C. (2003) Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res. 63, 7724-7732.
87. Kanwar, J. R., Shen, W. P., Kanwar, R. K., Berg, R. W., and Krissansen, G. W. (2001) Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J. Natl. Cancer Inst. 93, 1541-1552.
88. Mesri, M., Wall, N. R., Li, J., Kim, R. W., and Altieri, D. C. (2001) Cancer gene therapy using a survivin mutant adenovirus. J. Clin. Invest. 108, 981-990.
89. Jones, S. E. and Jomary, C. (2002) Clusterin. Int. J. Biochem. Cell Biol. 34, 427-431.
90. Miyake, H., Chi, K. N., and Gleave, M. E. (2000) Antisense TRPM-2 oligodeoxynucleotides chemosensitizes human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin. Cancer Res. 6, 1655-1663.
91. Zellweger, T., Miyake, H., July, L. V., Akbari, M., Kiyama, S., and Gleave, M. E. (2001) Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 3, 360-367.
92. Chi, K. N., Eisenhauer, E., and Fazli, L. (2004) A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of OGX-011, a 2′ methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to radical prostatectomy. Proc. Am. Soc. Clin. Oncol. 22, 30-33.
93. Chi, K. N., Eisenhauer, E., and Siu, L. (2005) A phase I study of a second generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel. Proc. Am. Soc. Clin. Oncol. 23, 3085.
94. Gleave, M. and Miyake, H. (2005) Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J. Urol. 23, 38-46.
95. Summerton, J. (1999) Morphonlino antisense oligomers: the case for an RNase H-independent structural type. Biochim. Biophys. Acta 1489, 141-158.